• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Pharmaceutical Sterility Testing Market Size

    ID: MRFR/HC/9236-HCR
    120 Pages
    Rahul Gotadki
    October 2025

    Pharmaceutical Sterility Testing Market Size, Growth Research Report By Sample (Sterile Drugs, Medical Devices, Biologics), By Product Type (Instruments, Kits & Reagents, Services), By Type (In-house, Outsourcing), By Test Type (Sterility Testing, Bioburden Testing, Bacterial Endotoxin Testing), By End User (Compounding Pharmacies, Medical Devices Companies, Pharmaceutical Companies), And B...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Pharmaceutical Sterility Testing Market Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Pharmaceutical Sterility Testing Size

    Pharmaceutical Sterility Testing Market Growth Projections and Opportunities

    The growing pharmaceutical industry is a key element energizing the interest for sterility testing. As the business encounters consistent development, the requirement for dependable and productive sterility testing techniques becomes principal. The pharmaceutical sterility testing market benefits from this development, driven by the turn of events and assembling of new medications, antibodies, and biopharmaceuticals. The rise in biopharmaceutical creation is a critical market powerhouse. Biologics, including monoclonal antibodies and quality treatments, require sterility testing procedures. The pharmaceutical sterility testing market answers this interest by offering trend setting innovations and administrations custom-made to the one-of-a-kind prerequisites of biopharmaceutical manufacturing. The globalization of the pharmaceutical production network straightforwardly affects sterility testing market elements. As pharmaceutical organizations extend their tasks worldwide, there is an uplifted emphasis on guaranteeing the sterility of items all through the inventory network. This drives the reception of strong sterility testing conventions and innovations to keep up with item respectability across different geographical areas. Quality confirmation stays a main concern for pharmaceutical producers. Sterility testing is a basic part of value confirmation processes, guaranteeing that pharmaceutical items fulfill the most high guidelines for security and viability. The market benefits from the business' unflinching obligation to keeping up with quality all through the item lifecycle. The developing pattern toward customized medication adds to the interest for specific sterility testing arrangements. Customized treatments often include remarkable details and assembling processes, requiring custom-made sterility testing draws near. The pharmaceutical sterility testing market advances to meet the requirements of customized medication, offering adjusted testing answers for individualized medicines. Pharmaceutical organizations are progressively outsourcing specific parts of their activities, including sterility testing. This market pattern is driven by the longing for cost-adequacy and ability access. Contract testing research centers represent considerable authority in pharmaceutical sterility testing experience uplifted request, adding to market development. Ongoing general health crises, for example, the Coronavirus pandemic, highlight the significance of fast and dependable sterility testing. The pharmaceutical sterility testing market observers expanded consideration and speculation during such disasters, as the business heightens endeavors to guarantee the sterility of basic pharmaceutical items, including immunizations and antiviral drugs.

    Pharmaceutical Sterility Testing Market Size Graph

    Market Summary

    The Global Pharmaceutical Sterility Testing Market is projected to grow from 0.67 USD Billion in 2024 to 1.19 USD Billion by 2035.

    Key Market Trends & Highlights

    Pharmaceutical Sterility Testing Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 5.37% from 2025 to 2032.
    • By 2035, the market valuation is anticipated to reach 1.19 USD Billion, indicating robust growth.
    • in 2024, the market is valued at 0.67 USD Billion, reflecting the increasing demand for sterility testing.
    • Growing adoption of advanced testing technologies due to stringent regulatory requirements is a major market driver.

    Market Size & Forecast

    2024 Market Size 0.67 (USD Billion)
    2035 Market Size 1.19 (USD Billion)
    CAGR (2025-2035) 5.30%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Merck KGaA (Germany), Rapid Micro Biosystems (US), Sartorius AG (Germany), Solvias AG (Switzerland), SGS SA (Switzerland), Boston Analytical (US), bioMérieux Inc. (France), Charles River Laboratories International Inc. (US), Thermo Fisher Scientific Inc. (US), Pace Analytical Services LLC (US), Toxikon Inc. (US)

    Market Trends

    Growing Pharmaceutical Companies & the Launch of More Drugs Will Accelerate Market Growth

    The development of pharmaceutical companies, the launch of more drugs, the rising prevalence of chronic diseases, and government support for the pharmaceutical industry are the main drivers of market CAGR for pharmaceutical sterility testing. For instance, in September 2016, Merck KGaA unveiled Steritest Symbio Pump system accessories. The attachments enable quicker and safer sterility verification in any environment.  The Centers for Disease Control and Prevention (CDC) estimate that in 2012, 117 million Americans had one or more chronic illnesses.

    The growth of the market is being aided by factors such as rising healthcare spending, an increase in pharmaceutical outsourcing, and technological advancements in direct immunization, membrane filtration, and quick sterility testing such as bacterial endotoxin testing.

    Over time, there have been more approvals and launches of novel medications. Around 53 innovative medications were authorized as new molecular entities under New Drug Applications (NDAs) by the US Food and Drug Administration (USFDA) Centre for Drug Evaluation and Research in 2020. The Pharma and Annual Review 2021 study states that 1,324 new medications were introduced to the market worldwide in 2020.

    The use of pharmaceutical sterility testing is increasing as a result of these new product launches, and growth in the  market for pharmaceutical sterility testing is anticipated over the coming years.  Additionally, pharmaceutical sterility testing is carried out at every stage of production in the pharmaceutical and biopharmaceutical industries to lessen the likelihood of product contamination. The growth of the biotechnology and pharmaceutical industries will consequently lead to a sharp rise in the overall need for pharmaceutical sterility testing in the coming years.

    The pharmaceutical sterility testing industry expanded as a result of more drugs being introduced to the market and increased R&D expenditures. In order to prevent product contamination and ensure that the pharmaceuticals are free of any live microorganisms, sterility is a crucial step in the manufacturing process. The market is being driven by a greater emphasis on quality and sterility, increased production and launch of drugs and medical devices, rising R&D activities in the pharmaceutical industry, and all of these factors together. Thus, driving the pharmaceutical sterility testing market revenue.

    The ongoing emphasis on stringent quality control measures in pharmaceutical manufacturing appears to drive the demand for robust sterility testing protocols, reflecting a broader commitment to patient safety and product integrity.

    U.S. Food and Drug Administration (FDA)

    Pharmaceutical Sterility Testing Market Market Drivers

    Market Growth Projections

    Growing Focus on Patient Safety

    The growing focus on patient safety is a fundamental driver of the Global Pharmaceutical Sterility Testing Market Industry. With increasing awareness of the implications of contaminated pharmaceutical products, stakeholders are prioritizing sterility testing as a critical component of quality assurance. This heightened emphasis on safety has led to the implementation of rigorous testing protocols and standards across the industry. Pharmaceutical companies are investing in comprehensive sterility testing to mitigate risks associated with contamination, thereby enhancing their product offerings. As patient safety remains a top priority, the demand for reliable sterility testing solutions is anticipated to grow, further propelling market dynamics.

    Stringent Regulatory Frameworks

    Stringent regulatory frameworks imposed by global health authorities significantly influence the Global Pharmaceutical Sterility Testing Market Industry. Regulatory agencies, such as the FDA and EMA, mandate comprehensive sterility testing for pharmaceutical products, particularly those intended for parenteral administration. Compliance with these regulations is crucial for market participants, as non-compliance can lead to severe penalties and product recalls. The emphasis on quality assurance and patient safety has led to increased investments in sterility testing technologies and services. As regulations evolve, the market is likely to adapt, fostering innovation and enhancing the reliability of sterility testing processes.

    Rising Demand for Biopharmaceuticals

    The increasing demand for biopharmaceuticals is a pivotal driver in the Global Pharmaceutical Sterility Testing Market Industry. As biopharmaceuticals require stringent sterility testing to ensure patient safety, the market is projected to grow from 0.67 USD Billion in 2024 to 1.19 USD Billion by 2035. This growth reflects a compound annual growth rate of 5.37% from 2025 to 2035. The surge in biopharmaceutical production necessitates robust sterility testing protocols, thereby propelling the demand for advanced testing methodologies and technologies. Regulatory bodies emphasize the importance of sterility assurance, further driving investments in testing services and equipment.

    Technological Advancements in Testing Methods

    Technological advancements in sterility testing methods are transforming the Global Pharmaceutical Sterility Testing Market Industry. Innovations such as rapid microbial detection technologies and automated testing systems enhance the efficiency and accuracy of sterility testing. These advancements not only reduce testing time but also improve the reliability of results, which is critical in ensuring product safety. The integration of advanced technologies, such as real-time monitoring and data analytics, further supports the industry's growth. As pharmaceutical companies seek to streamline their testing processes and comply with regulatory standards, the adoption of these technologies is expected to rise, driving market expansion.

    Expansion of Pharmaceutical Manufacturing Facilities

    The expansion of pharmaceutical manufacturing facilities globally is a significant driver of the Global Pharmaceutical Sterility Testing Market Industry. As companies scale up production to meet rising global healthcare demands, the need for effective sterility testing becomes increasingly critical. New manufacturing plants often incorporate advanced sterility testing laboratories to ensure compliance with regulatory standards. This trend is particularly evident in emerging markets, where investments in pharmaceutical infrastructure are on the rise. The establishment of these facilities not only boosts local economies but also enhances the overall capacity for sterility testing, thereby supporting market growth.

    Market Segment Insights

    Pharmaceutical Sterility Testing Sample Insights

    The market segments of pharmaceutical sterility testing, based on sample includes Sterile Drugs, Medical Devices, and Biologics. The sterile drugs segment dominated the market. All sorts of bacteria should be eliminated from sterile medications, and they should also be isotonic. Parenteral preparations and ophthalmic preparations are examples of sterile dosage forms.

    Pharmaceutical Sterility Testing Product Type Insights

    The pharmaceutical sterility testing market segmentation, based on product type, includes Instruments, Kits & Reagents, and Services. The kits & reagents category generated the most income. This increase is attributable to the accessibility of several items that aid in reducing the possibility of false negative and false positive outcomes. Another one of them is sterility testing pumps, which can be easily integrated into any testing environment and aid in maximizing safety and streamlining productivity. Over the anticipated period, segmental growth will be aided by the rising demand for comparable products.

    Pharmaceutical Sterility Testing Type Insights

    The market segmentation of pharmaceutical sterility testing, based on type, includes In-house and Outsourcing. The outsourcing category generated the most income. An appealing option is to outsource sterility testing. Since they do not have the resources to conduct reliable sterility testing in-house, small and medium-sized pharmaceutical and medical device firms would rather contract out these services to comply with FDA regulations. Additionally, outsourcing helps pharmaceutical and medical device businesses save money and time because they don't have to spend money on new equipment or hire and train personnel.

    Figure 1:  Pharmaceutical Sterility Testing Market, by Type, 2023 & 2032 (USD billion)

    Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

    Pharmaceutical Sterility Testing Test Type Insights

    The market segmentation of pharmaceutical sterility testing, based on test type, includes Sterility Testing, Bioburden Testing, and Bacterial Endotoxin Testing. The bacterial endotoxin testing category generated the most income. For all medications delivered parenterally, bacterial endotoxin testing is necessary. Medical items like implants are also tested using these procedures. The sector market is expanding due to the rising demand for parenteral medications and implants.

    Pharmaceutical Sterility Testing End User Insights

    The market segmentation of pharmaceutical sterility testing, based on end user, includes Compounding Pharmacies, Medical Devices Companies, and Pharmaceutical Companies. The pharmaceutical companies category generated the most income. Since most of these medications are taken orally by patients, pharmaceutical companies must perform sterility testing to ensure product safety, particularly for oral dosage forms. The needed sterility tests for a particular drug are detailed in each country's pharmacopeia according to established norms.

    Get more detailed insights about Pharmaceutical Sterility Testing Market Research Report—Global Forecast till 2032

    Regional Insights

    By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American pharmaceutical sterility testing market area will dominate this market. The expansion of the pharmaceutical businesses in the United States and Canada might explain this. The presence of numerous prominent market players in this area is anticipated to substantially impact the market's expansion. The region's market is expanding as a result of strict regulatory requirements for the sterility testing of medicines and medical equipment.

    Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 2:  PHARMACEUTICAL STERILITY TESTING MARKET SHARE BY REGION 2022 (%)

    PHARMACEUTICAL STERILITY TESTING MARKET SHARE BY REGION

    Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

    Europe pharmaceutical sterility testing market accounts for the second-largest market share due to elements including strict sterilization laws in the pharmaceutical and medical sectors, the rise in chronic disease prevalence, and the rising biotechnology and healthcare sectors. Further, the German market of pharmaceutical sterility testing held the largest market share, and the UK market of pharmaceutical sterility testing was the fastest growing market in the European region

    The Asia-Pacific Pharmaceutical sterility testing Market is expected to grow at the fastest CAGR from 2024 to 2032. This is a result of emerging countries increasingly harmonizing their regulatory norms with ICH standards. Additionally, several of the region's growing nations are adopting various steps to expand the domestic pharmaceutical industry and are enticing  corporations to establish operations there (collaborations that promote outsourcing activities). Such efforts are probably going to help with regional development.

    Moreover, China’s market of pharmaceutical sterility testing held the largest market share, and the Indian market of pharmaceutical sterility testing was the fastest growing market in the Asia-Pacific region.

    Key Players and Competitive Insights

    Leading market players are investing heavily in research and development in order to expand their product lines, which will help the market of pharmaceutical sterility testing, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, pharmaceutical sterility testing industry must offer cost-effective items.

    Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  pharmaceutical sterility testing industry to benefit clients and increase the market sector. In recent years, the pharmaceutical sterility testing industry has offered some of the most significant advantages to medicine.

    Major players in the pharmaceutical sterility testing market attempting to increase market demand by investing in research and development operations include Merck KGaA (Germany), Rapid Micro Biosystems (US), Sartorius AG (Germany), Solvias AG (Switzerland), SGS SA (Switzerland), Boston Analytical (US), bioMérieux Inc. (France), Charles River Laboratories International Inc. (US), Thermo Fisher Scientific Inc. (US), Pace Analytical Services LLC (US) and Toxikon Inc. (US).

    Charles River Laboratories, Inc offers services for clinical trials and drug development. The business provides testing and development services for vaccines, biosimilars, and medications for cancer, heart disease, bone conditions, endocrine disorders, and other diseases. Charles River Laboratories offers its services throughout the world. In September 2019, in order to test for endotoxins, Charles River Laboratories introduced the EndoScan-V software platform and the Celsis automated detection system.

    The Merck Group, also known as Merck, is a multinational science and technology firm with its headquarters in Darmstadt with operations in 66 different countries. Around 250 businesses make up the group, with Merck KGaA in Germany serving as its centerpiece. Three business segments make up the company: healthcare, life sciences, and electronics. As one of the biggest pharmaceutical corporations in the world and the oldest continuously operational chemical and pharmaceutical company, Merck was established in 1668.

    Key Companies in the Pharmaceutical Sterility Testing Market market include

    Industry Developments

    June 2022:In order to conduct on-site sterility testing for its GMP batches, Berkshire Sterile Manufacturing opened a sterility testing isolator. The business provides sterile filling of injectable medications, the majority of which are undergoing clinical studies or have a little commercial demand.

    August 2020:Emerson Resources Inc. was purchased by Pace Analytical Services, LLC. Emerson Resources Inc. is a contract production and manufacturing organization (CDMO) that specializes in producing clinical trial materials and developing drug forms for pharmaceutical companies. This purchase benefits pharmaceutical and biopharmaceutical clients by processing materials for phase 2 clinical trial research and development.

    Future Outlook

    Pharmaceutical Sterility Testing Market Future Outlook

    The Pharmaceutical Sterility Testing Market is projected to grow at a 5.30% CAGR from 2024 to 2032, driven by increasing regulatory demands and technological advancements.

    New opportunities lie in:

    • Invest in automation technologies to enhance testing efficiency and accuracy.
    • Develop novel sterility testing methods to meet evolving regulatory standards.
    • Expand service offerings to include comprehensive sterility testing solutions for emerging biopharmaceuticals.

    By 2035, the market is expected to exhibit robust growth, reflecting heightened demand for sterility assurance.

    Market Segmentation

    Pharmaceutical Sterility Testing Type Outlook

    • In-house
    • Outsourcing

    Pharmaceutical Sterility Testing Sample Outlook

    • Sterile Drugs
    • Medical Devices
    • Biologics

    Pharmaceutical Sterility Testing End User Outlook

    • Compounding Pharmacies
    • Medical Devices Companies
    • Pharmaceutical Companies

    Pharmaceutical sterility testing Regional Outlook

    North America
    • US
    • Canada

    Pharmaceutical Sterility Testing Test Type Outlook

    • Sterility Testing
    • Bioburden Testing
    • Bacterial Endotoxin Testing

    Pharmaceutical Sterility Testing Product Type Outlook

    • Instruments
    • Kits & Reagents
    • Services

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024 USD 0.674 billion
    Market Size 2035 1.19 (Value (USD Billion))
    Compound Annual Growth Rate (CAGR) 5.30% (2025 - 2035)
    Base Year 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2018-2022
    Market Forecast Units Value (USD Billion)
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Sample, Product Type, Type, Test Type, End User, and Region
    Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
    Countries Covered The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled Merck KGaA (Germany), Rapid Micro Biosystems (US), SGS SA (Switzerland), Boston Analytical (US), bioMérieux Inc. (France), Charles River Laboratories International Inc. (US), Sartorius AG (Germany), Solvias AG (Switzerland), Thermo Fisher Scientific Inc. (US), Pace Analytical Services LLC (US) and Toxikon Inc. (US)
    Key Market Opportunities New technological developments
    Key Market Dynamics Increasing drug approvals and new drug launches Increasing prevalence of patients suffering from cardiovascular diseases and cancer
    Market Size 2025 0.71 (Value (USD Billion))

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    How much is the pharmaceutical sterility testing market?

    The pharmaceutical sterility testing market size was valued at USD 0.63 Billion in 2023.

    What is the growth rate of the pharmaceutical sterility testing market?

    The market is projected to grow at a CAGR of 5.30% during the forecast period, 2024-2032.

    Which region held the largest market share in the pharmaceutical sterility testing market?

    North America had the largest share in the market

    Who are the key players in the pharmaceutical sterility testing market?

    The key players in the market are Merck KGaA (Germany), Rapid Micro Biosystems (US), Sartorius AG (Germany), Solvias AG (Switzerland), SGS SA (Switzerland), Boston Analytical (US), bioMérieux Inc. (France), Charles River Laboratories International Inc. (US), Thermo Fisher Scientific Inc. (US), Pace Analytical Services LLC (US) and Toxikon Inc. (US).

    Which sample led the pharmaceutical sterility testing market?

    The sterile drugs category dominated the market in 2022.

    Which type had the largest market share in the pharmaceutical sterility testing market?

    The outsourcing category had the largest share in the market.

    1. Table of Contents
    2. Executive Summary
    3. Market Introduction
      1. Definition
      2. Scope of the Study
        1. Research Objective
        2. Assumptions
        3. Limitations
    4. Research Methodology
      1. Overview
      2. Data Mining
      3. Secondary Research
      4. Primary Research
        1. Primary Interviews and Information Gathering Process
        2. Breakdown of Primary Respondents
      5. Forecasting Techniques
      6. Market Size Estimation
        1. Bottom-up Approach
        2. Top-Down Approach
      7. Data Triangulation
      8. Validation
    5. MARKET DYNAMICS
      1. Overview
      2. Drivers
      3. Restraints
      4. Opportunities
    6. MARKET FACTOR ANALYSIS
      1. Porter’s Five Forces Analysis
        1. Bargaining Power of Suppliers
        2. Bargaining Power of Buyers
        3. Threat of New Entrants
        4. Threat of Substitutes
        5. Intensity of Rivalry
      2. Value Chain Analysis
      3. COVID-19 Impact Analysis
        1. Market Impact Analysis
        2. Impact on Supply Chain
        3. Regional Impact
        4. Opportunity and Threat Analysis
    7. GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE
      1. Overview
      2. Sterile Drugs
    8. Market Estimates & Forecast, by Region, 2022–2030
    9. Market Estimates & Forecast, by Country, 2022–2030
      1. Medical Devices
    10. Market Estimates & Forecast, by Country, 2022–2030
      1. Biologics
    11. Market Estimates & Forecast, by Region, 2022–2030
    12. Market Estimates & Forecast, by Country, 2022–2030
    13. GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE
      1. Overview
      2. Instruments
    14. Market Estimates & Forecast, by Region, 2022–2030
    15. Market Estimates & Forecast, by Country, 2022–2030
      1. Kits & Reagents
      2. Services
    16. Market Estimates & Forecast, by Region, 2022–2030
    17. GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE
      1. Overview
      2. In-house
      3. Outsourcing
    18. Market Estimates & Forecast, by Country, 2022–2030
    19. GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE
      1. Overview
      2. Sterility Testing
      3. Bioburden Testing
      4. Bacterial Endotoxin Testing
    20. GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER
      1. Overview
      2. Compounding Pharmacies
      3. Medical Devices Companies
      4. Pharmaceutical Companies
      5. Others
    21. Market Estimates & Forecast, by Region, 2022–2030
    22. Market Estimates & Forecast, by Country, 2022–2030
    23. GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY REGION
      1. Overview
      2. North America
        1. US
        2. Canada
      3. Europe
        1. Germany
        2. France
        3. Italy
        4. Spain
        5. UK
        6. Rest of Europe
      4. Asia-Pacific
        1. Japan
        2. China
        3. India
        4. Australia
        5. South Korea
        6. Rest of Asia-Pacific
      5. Rest of the World
        1. Middle East
        2. Africa
        3. Latin America
    24. COMPANY LANDSCAPE
      1. Overview
      2. Competitive Analysis
      3. Market Share Analysis
      4. Major Growth Strategy in the Global Pharmaceutical Sterility Testing Market
      5. Competitive Benchmarking
      6. Leading Players in terms of Number of Developments in the Global Pharmaceutical Sterility Testing Market
      7. Key developments and Growth Strategies
        1. New Product Launch/Service Deployment
        2. Mergers & Acquisitions
        3. Joint Ventures
      8. Major Players Financial Matrix
        1. Sales & Operating Income, 2020
        2. Major Players R&D Expenditure, 2020
    25. COMPANY PROFILES
      1. Merck KGaA
        1. Company Overview
        2. Key Financials
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      2. Rapid Micro Biosystems
        1. Company Overview
        2. Key Financials
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      3. Sartorius AG
        1. Company Overview
        2. Key Financials
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      4. Solvias AG
        1. Company Overview
        2. Key Financials
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      5. SGS SA
        1. Company Overview
        2. Key Financials
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      6. Boston Analytical
        1. Company Overview
        2. Key Financials
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      7. BioMérieux, Inc.
        1. Company Overview
        2. Key Financials
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      8. Charles River Laboratories International, Inc.
        1. Company Overview
        2. Key Financials
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      9. Thermo Fisher Scientific, Inc.
        1. Company Overview
        2. Key Financials
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      10. Pace Analytical Services, LLC
        1. Company Overview
        2. Key Financials
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      11. Toxikon, Inc.
        1. Company Overview
        2. Key Financials
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      12. Sotera Health
        1. Company Overview
        2. Key Financials
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      13. Pacific Biolabs Inc.
        1. Company Overview
        2. Key Financials
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      14. STRERIS Corporation
        1. Company Overview
        2. Key Financials
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      15. WuXi AppTec
        1. Company Overview
        2. Key Financials
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
    26. APPENDIX
      1. References
      2. Related Reports
    27. List of Tables and Figures
      1. LIST OF TABLES
      2. TABLE 1 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET SYNOPSIS, 2022–2030
      3. TABLE 2 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET ESTIMATES & FORECAST, 2022– 2030 (USD MILLION)
      4. TABLE 3 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      5. TABLE 4 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      6. TABLE 5 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      7. TABLE 6 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      8. TABLE 7 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      9. TABLE 8 NORTH AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
      10. TABLE 9 NORTH AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      11. TABLE 10 NORTH AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      12. TABLE 11 NORTH AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      13. TABLE 12 NORTH AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      14. TABLE 13 NORTH AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      15. TABLE 14 US: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      16. TABLE 15 US: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      17. TABLE 16 US: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      18. TABLE 17 US: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      19. TABLE 18 US: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      20. TABLE 19 CANADA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      21. TABLE 20 CANADA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      22. TABLE 21 CANADA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      23. TABLE 22 CANADA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      24. TABLE 23 CANADA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      25. TABLE 24 EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
      26. TABLE 25 EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      27. TABLE 26 EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      28. TABLE 27 EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      29. TABLE 28 EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      30. TABLE 29 EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      31. TABLE 30 GERMANY: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      32. TABLE 31 GERMANY: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      33. TABLE 32 GERMANY: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      34. TABLE 33 GERMANY: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      35. TABLE 34 GERMANY: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      36. TABLE 35 FRANCE: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      37. TABLE 36 FRANCE: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      38. TABLE 37 FRANCE: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      39. TABLE 38 FRANCE: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      40. TABLE 39 FRANCE: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      41. TABLE 40 ITALY: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      42. TABLE 41 ITALY: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      43. TABLE 42 ITALY: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      44. TABLE 43 ITALY: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      45. TABLE 44 ITALY: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      46. TABLE 45 SPAIN: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      47. TABLE 46 SPAIN: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      48. TABLE 47 SPAIN: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      49. TABLE 48 SPAIN: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      50. TABLE 49 SPAIN: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      51. TABLE 50 UK: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      52. TABLE 51 UK: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      53. TABLE 52 UK: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      54. TABLE 53 UK: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      55. TABLE 54 UK: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      56. TABLE 55 REST OF EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      57. TABLE 56 REST OF EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      58. TABLE 57 REST OF EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      59. TABLE 58 REST OF EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      60. TABLE 59 REST OF EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      61. TABLE 60 ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
      62. TABLE 61 ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      63. TABLE 62 ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      64. TABLE 63 ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      65. TABLE 64 ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      66. TABLE 65 ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      67. TABLE 66 JAPAN: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      68. TABLE 67 JAPAN: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      69. TABLE 68 JAPAN: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      70. TABLE 69 JAPAN: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      71. TABLE 70 JAPAN: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      72. TABLE 71 CHINA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      73. TABLE 72 CHINA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      74. TABLE 73 CHINA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      75. TABLE 74 CHINA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      76. TABLE 75 CHINA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      77. TABLE 76 INDIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      78. TABLE 77 INDIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      79. TABLE 78 INDIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      80. TABLE 79 INDIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      81. TABLE 80 INDIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      82. TABLE 81 AUSTRALIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      83. TABLE 82 AUSTRALIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      84. TABLE 83 AUSTRALIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      85. TABLE 84 AUSTRALIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      86. TABLE 85 AUSTRALIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      87. TABLE 86 SOUTH KOREA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      88. TABLE 87 SOUTH KOREA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      89. TABLE 88 SOUTH KOREA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      90. TABLE 89 SOUTH KOREA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      91. TABLE 90 SOUTH KOREA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      92. TABLE 91 REST OF ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      93. TABLE 92 REST OF ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      94. TABLE 93 REST OF ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      95. TABLE 94 REST OF ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      96. TABLE 95 REST OF ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      97. TABLE 96 REST OF THE WORLD: PHARMACEUTICAL STERILITY TESTING MARKET, BY REGION, 2022–2030 (USD MILLION)
      98. TABLE 97 REST OF THE WORLD: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      99. TABLE 98 REST OF THE WORLD: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      100. TABLE 99 REST OF THE WORLD: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      101. TABLE 100 REST OF THE WORLD: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      102. TABLE 101 REST OF THE WORLD: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      103. TABLE 102 MIDDLE EAST: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      104. TABLE 103 MIDDLE EAST: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      105. TABLE 104 MIDDLE EAST: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      106. TABLE 105 MIDDLE EAST: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      107. TABLE 106 MIDDLE EAST: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      108. TABLE 107 AFRICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      109. TABLE 108 AFRICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      110. TABLE 109 AFRICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      111. TABLE 110 AFRICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      112. TABLE 111 AFRICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
      113. TABLE 112 LATIN AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
      114. TABLE 113 LATIN AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
      115. TABLE 114 LATIN AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
      116. TABLE 115 LATIN AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
      117. TABLE 116 LATIN AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION) LIST OF FIGURES
      118. FIGURE 1 RESEARCH PROCESS
      119. FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET
      120. FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET
      121. FIGURE 4 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY SAMPLE, 2020 (%)
      122. FIGURE 5 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY PRODUCT TYPE, 2020 (%)
      123. FIGURE 6 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY TYPE, 2020 (%)
      124. FIGURE 7 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY TEST TYPE, 2020 (%)
      125. FIGURE 8 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY END USER, 2020 (%)
      126. FIGURE 9 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY REGION, 2020 (%)
      127. FIGURE 10 NORTH AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY REGION, 2020 (%)
      128. FIGURE 11 EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY REGION, 2020 (%)
      129. FIGURE 12 ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY REGION, 2020 (%)
      130. FIGURE 13 REST OF THE WORLD: PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY REGION, 2020 (%)
      131. FIGURE 14 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
      132. FIGURE 15 MERCK KGAA PHARMACEUTICALS: FINANCIAL OVERVIEW
      133. FIGURE 16 MERCK KGAA PHARMACEUTICALS: SWOT ANALYSIS
      134. FIGURE 17 RAPID MICRO BIOSYSTEMS: FINANCIAL OVERVIEW
      135. FIGURE 18 RAPID MICRO BIOSYSTEMS: SWOT ANALYSIS
      136. FIGURE 19 SARTORIUS AG: FINANCIAL OVERVIEW
      137. FIGURE 20 SARTORIUS AG: SWOT ANALYSIS
      138. FIGURE 21 SOLVIAS AG: FINANCIAL OVERVIEW
      139. FIGURE 22 SOLVIAS AG: SWOT ANALYSIS
      140. FIGURE 23 SGS SA: FINANCIAL OVERVIEW
      141. FIGURE 24 SGS SA: SWOT ANALYSIS
      142. FIGURE 25 BOSTON ANALYTICAL: FINANCIAL OVERVIEW
      143. FIGURE 26 BOSTON ANALYTICAL: SWOT ANALYSIS
      144. FIGURE 27 BIOMÉRIEUX, INC.: FINANCIAL OVERVIEW
      145. FIGURE 28 BIOMÉRIEUX, INC.: SWOT ANALYSIS
      146. FIGURE 29 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: FINANCIAL OVERVIEW
      147. FIGURE 30 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: SWOT ANALYSIS
      148. FIGURE 31 THERMO FISHER SCIENTIFIC, INC.: FINANCIAL OVERVIEW
      149. FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: SWOT ANALYSIS
      150. FIGURE 33 PACE ANALYTICAL SERVICES, LLC: FINANCIAL OVERVIEW
      151. FIGURE 34 PACE ANALYTICAL SERVICES, LLC: SWOT ANALYSIS
      152. FIGURE 35 TOXIKON, INC.: FINANCIAL OVERVIEW
      153. FIGURE 36 TOXIKON, INC.: SWOT ANALYSIS
      154. FIGURE 37 SOTERA HEALTH: FINANCIAL OVERVIEW
      155. FIGURE 38 SOTERA HEALTH: SWOT ANALYSIS
      156. FIGURE 39 PACIFIC BIOLABS INC.: FINANCIAL OVERVIEW
      157. FIGURE 40 PACIFIC BIOLABS INC.: SWOT ANALYSIS
      158. FIGURE 41 STRERIS CORPORATION: FINANCIAL OVERVIEW
      159. FIGURE 42 STRERIS CORPORATION: SWOT ANALYSIS
      160. FIGURE 43 WUXI APPTEC: FINANCIAL OVERVIEW
      161. FIGURE 44 WUXI APPTEC: SWOT ANALYSIS

    Market Segmentation

    Pharmaceutical Sterility Testing Sample Outlook (USD Billion, 2018-2032)

    ·         Sterile Drugs

    ·         Medical Devices

    ·         Biologics

    Pharmaceutical Sterility Testing Product Type Format Outlook (USD Billion, 2018-2032)

    ·         Instruments

    ·         Kits & Reagents

    ·         Services

    Pharmaceutical Sterility Testing Type Outlook (USD Billion, 2018-2032)

    ·         In-house

    ·         Outsourcing 

    Pharmaceutical Sterility Testing Test Type Outlook (USD Billion, 2018-2032)

    ·         Sterility Testing

    ·         Bioburden Testing

    ·         Bacterial Endotoxin Testing

    Pharmaceutical Sterility Testing End User Outlook (USD Billion, 2018-2032)

    ·         Compounding Pharmacies

    ·         Medical Devices Companies

    ·         Pharmaceutical Companies

    Pharmaceutical Sterility Testing Regional Outlook (USD Billion, 2018-2032)

    ·         North America Outlook (USD Billion, 2018-2032)

    o   North America Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   North America Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   North America Pharmaceutical Sterility Testing by Type

    §   In-House  

    §  Outsourcing 

    o   North America Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o    North America Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §  Pharmaceutical Companies

    o   US Outlook (USD Billion, 2018-2032)

    o   US Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   US Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   US Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing 

    o   US Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o    US Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §  Pharmaceutical Companies

    o   CANADA Outlook (USD Billion, 2018-2032)

    o   CANADA Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   CANADA Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   CANADA Pharmaceutical Sterility Testing by Type

    §  In-House

    §  Outsourcing 

    o   CANADA Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   CANADA Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §  Pharmaceutical Companies

    ·         Europe Outlook (USD Billion, 2018-2032)

    o    Europe Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   Europe Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   Europe Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing 

    o   Europe Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   Europe Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §  Pharmaceutical Companies

    o   Germany Outlook (USD Billion, 2018-2032)

    o   Germany Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   Germany Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   Germany Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing 

    o   Germany Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   Germany Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §  Pharmaceutical Companies

    o   France Outlook (USD Billion, 2018-2032)

    o   France Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   France Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   France Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing 

    o   France Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   France Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §  Pharmaceutical Companies

    o   UK Outlook (USD Billion, 2018-2032)

    o   UK Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   UK Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   UK Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing 

    o   UK Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   UK Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §  Pharmaceutical Companies

    o   ITALY Outlook (USD Billion, 2018-2032)

    o   ITALY Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   ITALY Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   ITALY Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing 

    o   ITALY Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   ITALY Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §  Pharmaceutical Companies

    o   SPAIN Outlook (USD Billion, 2018-2032)

    o   Spain Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   Spain Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   Spain Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing 

    o   Spain Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   Spain Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §  Pharmaceutical Companies

    o   Rest Of Europe Outlook (USD Billion, 2018-2032)

    o   Rest Of Europe Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   REST OF EUROPE Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   REST OF EUROPE Pharmaceutical Sterility Testing by Type

    §  In-House

    §  Outsourcing 

    o   REST OF EUROPE Pharmaceutical Sterility Testing by Test Type

    §  Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   REST OF EUROPE Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §  Pharmaceutical Companies

    ·         Asia-Pacific Outlook (USD Billion, 2018-2032)

    o    Asia-Pacific Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   Asia-Pacific Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   Asia-Pacific Pharmaceutical Sterility Testing by Type

    §  In-house

    §  Outsourcing 

    o   Asia-Pacific Pharmaceutical Sterility Testing by Test Type

    §  Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   Asia-Pacific Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §   Pharmaceutical Companies

    o   China Outlook (USD Billion, 2018-2032)

    o   China Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   China Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   China Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing 

    o   China Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   China Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §  Pharmaceutical Companies

    o   Japan Outlook (USD Billion, 2018-2032)

    o   Japan Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   Japan Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   Japan Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing 

    o   Japan Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   Japan Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §  Pharmaceutical Companies

    o   India Outlook (USD Billion, 2018-2032)

    o   India Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   India Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   India Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing 

    o   India Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   India Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §  Pharmaceutical Companies

    o   Australia Outlook (USD Billion, 2018-2032)

    o   Australia Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   Australia Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   Australia Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing 

    o   Australia Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   Australia Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §  Pharmaceutical Companies

    o   Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)

    o   Rest of Asia-Pacific Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   Rest of Asia-Pacific Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   Rest of Asia-Pacific Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing   

    o   Rest of Asia-Pacific Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   Rest of Asia-Pacific Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §   Pharmaceutical Companies

    ·         Rest of the World Outlook (USD Billion, 2018-2032)

    o    Rest of the World Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   Rest of the World Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   Rest of the World Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing 

    o   Rest of the World Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   Rest of the World Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §   Pharmaceutical Companies

    o   Middle East Outlook (USD Billion, 2018-2032)

    o   Middle East Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   Middle East Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   Middle East Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing 

    o   Middle East Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   Middle East Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §   Pharmaceutical Companies

    o   Africa Outlook (USD Billion, 2018-2032)

    o   Africa Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   Africa Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   Africa Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing 

    o   Africa Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing

    o   Africa Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §   Pharmaceutical Companies

    o   Latin America Outlook (USD Billion, 2018-2032)

    o   Latin America Pharmaceutical Sterility Testing by Sample

    §  Sterile Drugs

    §  Medical Devices

    §  Biologics

    o   Latin America Pharmaceutical Sterility Testing by Product Type Format

    §  Instruments

    §  Kits & Reagents

    §  Services

    o   Latin America Pharmaceutical Sterility Testing by Type

    §   In-House

    §  Outsourcing 

    o   Latin America Pharmaceutical Sterility Testing by Test Type

    §   Sterility Testing

    §  Bioburden Testing

    §  Bacterial Endotoxin Testing  

    o   Latin America Pharmaceutical Sterility Testing by End User

    §  Compounding Pharmacies

    §  Medical Devices Companies

    §   Pharmaceutical Companies

    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027